Yamamura Y, Sakatani M, Ogura T, Azuma I
Cancer. 1979 Apr;43(4):1314-9. doi: 10.1002/1097-0142(197904)43:4<1314::aid-cncr2820430420>3.0.co;2-6.
Four hundred fifty-five patients with lung cancer were treated with oil-attached cell-wall skeleton of bacillus Calmette-Guérin (BCG-CWS) as adjuvant immunotherapy following initial conventional therapy. The overall survival period of the patients was prolonged significantly as compared with that of 380 patients in a historical control group receiving initial conventional therapy alone (p less than 0.0001). The prolongation of the survival period of the patients was also statistically significant when classified according to clinical stages and histological cell types. The therapeutic effect was remarkable in patients combined with malignant pleurisy. Intrapleural injection of BCG-CWS resulted in not only prevention of accumulation of pleural effusion and abrogation of tumor cells but also in prolongation of survival period (P = 0.016). No serious side effects due to BCG-CWS were experienced. From the previous experimental studies and clinical experiences with human tumors, it can be concluded that adjuvant immunotherapy with BCG-CWS is a useful therapeutic modality for lung cancer, especially in cases combined with malignant pleurisy.
455例肺癌患者在接受初始常规治疗后，采用卡介苗细胞壁骨架（BCG-CWS）进行辅助免疫治疗。与仅接受初始常规治疗的380例历史对照组患者相比，这些患者的总生存期显著延长（p<0.0001）。根据临床分期和组织学细胞类型分类时，患者生存期的延长也具有统计学意义。该治疗方法对合并恶性胸膜炎的患者疗效显著。胸腔内注射BCG-CWS不仅可防止胸腔积液积聚和消除肿瘤细胞，还可延长生存期（P=0.016）。未出现因BCG-CWS引起的严重副作用。从以往对人类肿瘤的实验研究和临床经验可以得出结论，BCG-CWS辅助免疫治疗是肺癌的一种有效治疗方式，尤其是对于合并恶性胸膜炎的病例。
